By Ben Hirschler LONDON (Reuters) - The idea of using vaccines to fight cancer has received a shot in the arm from a $1 billion deal between Bristol-Myers Squibb and Bavarian Nordic. The agreement gives the U.S. drugmaker an exclusive option to the Danish biotech firm's therapeutic prostate cancer vaccine Prostvac and signals that such shots may have a bright future when combined with so-called checkpoint inhibitor drugs. Shares in Bavarian Nordic surged 35 percent on Wednesday on news of the Bristol-Myers tie-up, under which it could receive up to $975 million, including an upfront payment of $60 million. Unlike traditional preventative vaccines, therapeutic ones are designed for people with established disease and the aim is to boost the patient's immune system to keep tumors at bay. via Health News Headlines - Yahoo News Read More Here..
No comments:
Post a Comment